29:
680:
299:
PXL065 was discovered and advanced to Phase 1 by DeuteRx, LLC using the strategy of deuterium-enabled chiral switching (DECS). In August 2018, PXL065 and a portfolio of deuterated thiazolidinediones (TZDs) was acquired by Poxel SA.
745:
475:
Harrison, Stephen A.; Thang, Carole; Bolze, Sébastien; DeWitt, Sheila; Hallakou-Bozec, Sophie; Dubourg, Julie; Bedossa, Pierre; Cusi, Kenneth; Ratziu, Vlad; Grouin, Jean-Marie; Moller, David E.; Fouqueray, Pascale (2023).
425:
Monternier, Pierre-Axel; Singh, Jaspreet; Parasar, Parveen; Theurey, Pierre; Dewitt, Sheila; Jacques, Vincent; Klett, Eric; Kaur, Navtej; Nagaraja, Tavarekere N.; Moller, David E.; Hallakou-Bozec, Sophie (2022).
368:
Jacques, Vincent; Bolze, Sébastien; Hallakou-Bozec, Sophie; Czarnik, Anthony W.; Divakaruni, Ajit S.; Fouqueray, Pascale; Murphy, Anne N.; Van der Ploeg, Lex H.T.; DeWitt, Sheila (2021-04-10).
296:(X-ALD). In 2022, it successfully completed a 9 month Phase 2 trial in biopsy-proven NASH patients where it met the primary endpoint for reduction in liver fat without weight gain or edema.
208:
292:
agonist activity and the associated side effects of weight gain and edema. PXL065 (formerly known as DRX-065) has demonstrated preclinical efficacy for both NASH and X-linked
653:"Poxel Expands Metabolic Pipeline Through Strategic Acquisition Agreement with DeuteRx for DRX-065, a Novel Clinical Stage Drug Candidate for NASH, and Other Programs"
289:
652:
523:
222:
524:"Poxel Announces Positive Results from Phase 2 NASH Trial (DESTINY-1) for PXL065, A Novel, Proprietary Deuterium-Stabilized R-Stereoisomer of Pioglitazone"
250:
InChI=1S/C19H20N2O3S/c1-2-13-3-6-15(20-12-13)9-10-24-16-7-4-14(5-8-16)11-17-18(22)21-19(23)25-17/h3-8,12,17H,2,9-11H2,1H3,(H,21,22,23)/t17-/m1/s1/i17D
478:"Evaluation of PXL065 – deuterium-stabilized (R)-pioglitazone in patients with NASH: A phase II randomized placebo-controlled trial (DESTINY-1)"
721:
370:"Deuterium-Stabilized (R)-Pioglitazone (PXL065) Is Responsible for Pioglitazone Efficacy in NASH yet Exhibits Little to No PPARγ Activity"
242:
57:
755:
273:
123:
750:
740:
714:
597:"Deuterium-Enabled Chiral Switching (DECS) Yields Chirally Pure Drugs from Chemically Interconverting Racemates"
770:
428:"Therapeutic potential of deuterium-stabilized ('R')-pioglitazone - PXL065 for X-linked adrenoleukodystrophy"
760:
707:
293:
78:
765:
505:
634:
616:
577:
569:
497:
457:
407:
389:
87:
624:
608:
561:
489:
447:
439:
397:
381:
148:
132:
341:
691:
629:
596:
452:
427:
402:
369:
734:
549:
509:
112:
687:
612:
285:
28:
565:
493:
281:
184:
620:
573:
393:
477:
317:
638:
581:
501:
461:
411:
679:
443:
98:
20:
385:
595:
DeWitt, Sheila; Czarnik, Anthony W.; Jacques, Vincent (2020-10-08).
746:
Experimental drugs developed for non-alcoholic fatty liver disease
337:
207:
198:
69:)-5-Deuterio-5-phenyl]methyl]-1,3-thiazolidine-2,4-dione
695:
316:
About the chemical formula: One of the hydrogens is
196:
183:
147:
142:
122:
97:
77:
48:
40:
35:
554:Nature Reviews Gastroenterology & Hepatology
230:1(C(=O)NC(=O)S1)CC2=CC=C(C=C2)OCCC3=NC=C(C=C3)CC
111:
86:
715:
550:"Safer pioglitazone alternative is effective"
8:
19:
272:) is a drug candidate for the treatment of
722:
708:
344:for deuterium should be H, rather than D).
27:
628:
451:
401:
131:
276:(NASH). It is the deuterium-stabilized (
357:
309:
247:
227:
62:
432:Journal of Inherited Metabolic Disease
18:
7:
676:
674:
363:
361:
102:
14:
678:
320:, so a more precise formula is C
165:
159:
601:ACS Medicinal Chemistry Letters
255:Key:HYAFETHFCAUJAY-VHLRUQIKSA-N
613:10.1021/acsmedchemlett.0c00052
177:
171:
153:
1:
694:. You can help Knowledge by
274:nonalcoholic steatohepatitis
787:
673:
566:10.1038/s41575-023-00764-5
494:10.1016/j.jhep.2023.02.004
143:Chemical and physical data
374:Hepatology Communications
238:
218:
53:
44:DRX-065; d-R-pioglitazone
26:
690:-related article is a
482:Journal of Hepatology
756:Deuterated compounds
340:recommends that the
294:adrenoleukodystrophy
23:
751:Thiazolidinediones
741:Pharmacology stubs
548:Fyfe, Ian (2023).
444:10.1002/jimd.12510
703:
702:
607:(10): 1789–1792.
386:10.1002/hep4.1723
263:
262:
209:Interactive image
16:Chemical compound
778:
724:
717:
710:
682:
675:
668:
667:
665:
664:
649:
643:
642:
632:
592:
586:
585:
545:
539:
538:
536:
535:
520:
514:
513:
472:
466:
465:
455:
422:
416:
415:
405:
380:(8): 1412–1425.
365:
345:
314:
270:d-R-pioglitazone
211:
191:
179:
173:
167:
161:
155:
135:
115:
105:
104:
90:
31:
24:
22:
786:
785:
781:
780:
779:
777:
776:
775:
771:Ethyl compounds
731:
730:
729:
728:
672:
671:
662:
660:
651:
650:
646:
594:
593:
589:
547:
546:
542:
533:
531:
522:
521:
517:
474:
473:
469:
424:
423:
419:
367:
366:
359:
354:
349:
348:
342:chemical symbol
335:
331:
327:
323:
315:
311:
306:
259:
256:
251:
246:
245:
234:
231:
226:
225:
214:
189:
176:
170:
164:
158:
138:
118:
101:
93:
73:
70:
61:
60:
17:
12:
11:
5:
784:
782:
774:
773:
768:
763:
758:
753:
748:
743:
733:
732:
727:
726:
719:
712:
704:
701:
700:
683:
670:
669:
644:
587:
540:
515:
488:(5): 914–925.
467:
438:(4): 832–847.
417:
356:
355:
353:
350:
347:
346:
333:
329:
325:
321:
308:
307:
305:
302:
261:
260:
258:
257:
254:
252:
249:
241:
240:
239:
236:
235:
233:
232:
229:
221:
220:
219:
216:
215:
213:
212:
204:
202:
194:
193:
187:
181:
180:
174:
168:
162:
156:
151:
145:
144:
140:
139:
137:
136:
128:
126:
120:
119:
117:
116:
108:
106:
95:
94:
92:
91:
83:
81:
75:
74:
72:
71:
64:
56:
55:
54:
51:
50:
46:
45:
42:
38:
37:
33:
32:
15:
13:
10:
9:
6:
4:
3:
2:
783:
772:
769:
767:
764:
762:
761:Phenol ethers
759:
757:
754:
752:
749:
747:
744:
742:
739:
738:
736:
725:
720:
718:
713:
711:
706:
705:
699:
697:
693:
689:
684:
681:
677:
658:
654:
648:
645:
640:
636:
631:
626:
622:
618:
614:
610:
606:
602:
598:
591:
588:
583:
579:
575:
571:
567:
563:
559:
555:
551:
544:
541:
529:
525:
519:
516:
511:
507:
503:
499:
495:
491:
487:
483:
479:
471:
468:
463:
459:
454:
449:
445:
441:
437:
433:
429:
421:
418:
413:
409:
404:
399:
395:
391:
387:
383:
379:
375:
371:
364:
362:
358:
351:
343:
339:
319:
313:
310:
303:
301:
297:
295:
291:
287:
283:
279:
275:
271:
267:
253:
248:
244:
237:
228:
224:
217:
210:
206:
205:
203:
200:
195:
188:
186:
182:
152:
150:
146:
141:
134:
130:
129:
127:
125:
121:
114:
110:
109:
107:
100:
96:
89:
85:
84:
82:
80:
76:
68:
63:
59:
52:
47:
43:
39:
36:Clinical data
34:
30:
25:
696:expanding it
688:pharmacology
685:
661:. Retrieved
659:. 2018-08-30
656:
647:
604:
600:
590:
557:
553:
543:
532:. Retrieved
530:. 2022-08-30
527:
518:
485:
481:
470:
435:
431:
420:
377:
373:
312:
298:
288:which lacks
286:pioglitazone
277:
269:
265:
264:
88:1259828-75-5
66:
192: g·mol
49:Identifiers
41:Other names
735:Categories
663:2024-03-02
560:(4): 201.
534:2024-03-02
352:References
282:enantiomer
197:3D model (
185:Molar mass
133:RQ8IV9N7OT
79:CAS Number
58:IUPAC name
766:Pyridines
621:1948-5875
574:1759-5053
510:257034807
394:2471-254X
318:deuterium
657:Poxel SA
639:33062153
582:36882559
528:Poxel SA
502:36804402
462:35510808
412:34430785
113:49835993
630:7549104
453:9545763
403:8369945
149:Formula
99:PubChem
637:
627:
619:
580:
572:
508:
500:
460:
450:
410:
400:
392:
266:PXL065
223:SMILES
190:356.44
21:PXL065
686:This
506:S2CID
338:IUPAC
304:Notes
290:PPARγ
243:InChI
199:JSmol
692:stub
635:PMID
617:ISSN
578:PMID
570:ISSN
498:PMID
458:PMID
408:PMID
390:ISSN
124:UNII
625:PMC
609:doi
562:doi
490:doi
448:PMC
440:doi
398:PMC
382:doi
336:S (
284:of
103:CID
737::
655:.
633:.
623:.
615:.
605:11
603:.
599:.
576:.
568:.
558:20
556:.
552:.
526:.
504:.
496:.
486:78
484:.
480:.
456:.
446:.
436:45
434:.
430:.
406:.
396:.
388:.
376:.
372:.
360:^
328:HN
326:19
322:19
280:)-
163:20
157:19
65:(5
723:e
716:t
709:v
698:.
666:.
641:.
611::
584:.
564::
537:.
512:.
492::
464:.
442::
414:.
384::
378:5
334:3
332:O
330:2
324:H
278:R
268:(
201:)
178:S
175:3
172:O
169:2
166:N
160:H
154:C
67:R
Text is available under the Creative Commons Attribution-ShareAlike License. Additional terms may apply.
